Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine ER for Chronic Cough in Idiopathic Pulmonary Fibrosis
NCT07671911Phase 3Recruiting
- Sponsor
- Trevi Therapeutics
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 3 trial of nalbuphine in chronic cough, sponsored by Trevi Therapeutics. Started Jun 2026; status: recruiting.
02
Drugs
nalbuphine
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT07671911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671911.